Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Regdanvimab (CT-P59) is a human monoclonal antibody designed to target the receptor-binding domain of the SARS-CoV-2 spike protein, thereby inhibiting the virus's ability to enter cells by blocking its interaction with the ACE2 receptor. It is utilized in the research of COVID-19 [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Regdanvimab (CT-P59) is a human monoclonal antibody designed to target the receptor-binding domain of the SARS-CoV-2 spike protein, thereby inhibiting the virus's ability to enter cells by blocking its interaction with the ACE2 receptor. It is utilized in the research of COVID-19 [1]. |
Molecular Weight | N/A |
CAS No. | 2444308-95-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Regdanvimab 2444308-95-4 inhibitor inhibit